Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | ovarian cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | ovarian cancer | sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment resulted in an objective response rate of 11.5% (3/26, 1 complete response, 2 partial response) and stable disease in 26.9% (7/26) of patients with CD274 (PD-L1)-positive ovarian cancer, with a median progression-free survival of 1.9 months and a median overall survival of 13.8 months (PMID: 29095678, PMID: 30522700; NCT02054806). | 29095678 30522700 |
PubMed Id | Reference Title | Details |
---|---|---|
(29095678) | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. | Full reference... |
(30522700) | Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. | Full reference... |